samplefor GH and appetite regulation
99%+ · 5mg · Lyophilized
Bulk discount
3+ pcs
€21.75
−5%
5+ pcs
€20.61
−10%
10+ pcs
€19.46
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
GHRP-6
Growth Hormone Secretagogue | GH Release & Cardioprotection
In short
Synthetic hexapeptide and ghrelin receptor agonist studied for stimulating somatotropic secretion and appetite.
Best sellers
Related resources
Ready-to-use starter kit
GHRP-6 is a synthetic peptide consisting of six amino acids that belongs to the class of growth hormone secretagogues. At the molecular level, it interacts with ghrelin receptors (GHS-R1a) and the CD36 receptor, triggering specific intracellular pathways to stimulate the release of growth hormone. Researchers study this molecule in laboratory settings (in vitro) and animal models to evaluate its potential cardioprotective and cytoprotective mechanisms. This product is strictly for scientific research purposes and is not an approved medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone release through activation of the ghrelin receptor (GHS-R1a) and CD36 receptor. Developed in the 1980s as one of the first growth hormone secretagogues, it acts through a PKC/calcium-dependent pathway distinct from GHRH. Beyond GH release, GHRP-6 has demonstrated significant cardioprotective, wound healing, and cytoprotective properties in preclinical and early clinical research. It is notable for its strong appetite-stimulating effects via direct ghrelin receptor activation and its synergistic interaction with GHRH-class peptides.
First GHRP in class (Bowers 1980s) GH +10-15x baseline at 1 mcg/kg Ghrelin-mimicking appetite stimulation Pre-ipamorelin clinical reference
Activates GHS-R1a (ghrelin receptor) for GH release through a PKC/calcium-dependent, cAMP-independent pathway via diacylglycerol/inositol trisphosphate signaling at both pituitary and hypothalamic sites. Separately acts as a CD36 receptor antagonist, blocking fatty acid uptake and providing cytoprotective and cardioprotective effects by preventing lipotoxicity. Requires endogenous GHRH for maximal GH stimulation—GHRH antagonist reduces GHRP-6-induced GH response by ~80% (Pandya et al., 1998). Exhibits tachyphylaxis with continuous exposure, necessitating pulsed dosing strategies.
Potent GH secretagogue with dose-dependent release demonstrated in human clinical studies via GHS-R1a activation
Simultaneous stimulation with GHRH-class peptides produces synergistic GH response 2-3x greater than either alone
Sustained GH release increases downstream IGF-1 for anabolic and tissue repair support
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
2-3 hours after eating, 30 minutes before next meal. Bedtime dose most important.
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
2-3 hours after eating, 30 minutes before next meal. Bedtime dose most important.
Allow vial to reach room temperature (15-20 minutes)
Clean vial top with alcohol swab and allow to dry
Calculate required bacteriostatic water volume using the calculator below
Draw calculated volume of bacteriostatic water into syringe
Inject water slowly down the inside wall of the vial (never directly onto powder)
Gently swirl until powder completely dissolves (never shake)
Solution should be clear - discard if cloudy or contains particles
Store reconstituted solution in refrigerator at 2-8°C
Proven safe in human Phase I dose-escalation trial with IV administration
Strong appetite increase is expected (ghrelin receptor activation) - not an adverse effect
Transiently elevates cortisol and prolactin, particularly at doses above 100mcg
May increase blood glucose and reduce insulin sensitivity with prolonged use - monitor if diabetic or insulin resistant
Avoid use in active cancer - / elevation may promote tumor growth
Must inject on empty stomach - food significantly blunts response
Less selective than ipamorelin (elevates cortisol, prolactin, and appetite)
No pharmacological interaction with beta-blocker metoprolol demonstrated in clinical studies
Prolonged continuous use may lead to ghrelin receptor (GHS-R1a) desensitization, reducing response. Cycling (8-12 weeks on, 4-8 weeks off) recommended to maintain efficacy.
Compatibility
The pairings below come from research literature and established biohacker stacking patterns. Click a card for the full reasoning - when the partner is in our catalog you'll see a direct order link too.
This is a literature overview, not medical advice. Pairs not listed are not proven safe - they simply lack enough published data.
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Cytoprotective Effects Review (2017)
Systematic review | PubMed/MEDLINE | 1980-2017 | Multi-organ cytoprotection
Comprehensive review establishing GHRPs as cytoprotective agents beyond GH secretion. GHRP-6 demonstrated pharmacological preconditioning across cardiac, renal, pulmonary, and intestinal tissues during ischemia/reperfusion injury via PI-3K/AKT1 pathway activation.
View the studyPrevention of Doxorubicin Cardiotoxicity (2024)
Rats | 400μg/kg IP twice daily | 52 days | Complete cardiac function preservation
Concurrent GHRP-6 administration completely prevented dilated cardiomyopathy in doxorubicin-treated rats, preserving left ventricular systolic function through Bcl-2 upregulation, mitochondrial preservation, and multi-organ protection.
View the studyPhase I/II Acute Ischemic Stroke Trial (2024)
Human | 36 patients | EGF + GHRP-6 (3.5mg or 5mg IV) | 7 days treatment | 180-day follow-up
Randomized clinical trial of EGF + GHRP-6 combination in acute ischemic stroke. Treated groups showed favorable neurological and functional evolution at 90 and 180 days with higher survival rate and fewer serious adverse events (20-30% vs 56.2% in controls).
View the studyGHRP-6 Requires Endogenous GHRH for Maximal GH Stimulation (1998)
Human | 9 healthy males | GHRP-6 with/without GHRH antagonist | Single dose
Landmark study demonstrating that GHRH antagonist eliminated most of the GH response to GHRP-6 (maximal GH dropped from 33.8 to 6.2 μg/L), establishing that endogenous GHRH is required for optimal GHRP-6 effectiveness.
View the studyWound Healing and Hypertrophic Scar Prevention (2016)
Rats + Rabbits | Topical 400μg/ml | 4-30 days | Accelerated closure and 90.5% scar prevention
Topical GHRP-6 significantly enhanced wound closure within 24 hours in rat model. In rabbit hypertrophic scar model, aborted scar formation in 90.5% of treated wounds through TGF-β1/CTGF downregulation and PPARG upregulation.
View the studyPharmacokinetic Study in Healthy Volunteers
Human | 9 healthy males | IV administration | Phase I dose-escalation
First human pharmacokinetic characterization of GHRP-6. Bi-exponential disposition with distribution half-life of 7.6±1.9 minutes and elimination half-life of 2.5±1.1 hours. Proven safe across dose-escalation protocol.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
